These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer. Shiihara J, Ohyanagi F, Amari H, Toda M, Tahara H, Yuzawa M, Maeda Y, Nomura M, Mizushina Y, Nagai Y, Ohta H, Yamaguchi Y. Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792 [Abstract] [Full Text] [Related]
8. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report. Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N. Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916 [Abstract] [Full Text] [Related]
18. Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib. Zhang Y, Qin Y, Xu H, Yao Q, Gao Y, Feng Y, Ren J. Pathol Oncol Res; 2021 Jul; 27():637745. PubMed ID: 34257603 [Abstract] [Full Text] [Related]